|
1.
|
|
8 p, 1.1 MB |
Oncological care organisation during COVID-19 outbreak
/
Onesti, Concetta Elisa (University of Liège. Giga Research Institute) ;
Rugo, Hope S. (University of California San Francisco. Department of Medicine) ;
Generali, Daniele (University of Trieste) ;
Peeters, Marc (University Hospital Antwerp (Bèlgica)) ;
Zaman, Khalil (CHUV-Centre Hospitalier Universitaire Vaudois. Oncology Department) ;
Wildiers, Hans (University Hospitals Leuven (Bèlgica)) ;
Harbeck, Nadia (Ludwig Maximilians University Hospital) ;
Martin, Miguel (Universidad Complutense de Madrid. Departamento de Medicina) ;
Cristofanilli, Massimo (Northwestern University) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Tjan-Heijnen, Vivianne (Maastricht University Medical Center) ;
Hurvitz, Sara A. (University of California Los Angeles) ;
Berchem, Guy (Centre Hospitalier de Luxembourg. Hemato-Oncology Department) ;
Tagliamento, Marco (Ospedale Policlinico San Martino) ;
Campone, Mario (Institut de Cancérologie de l'Ouest. Centre René Gauducheau) ;
Bartsch, Rupert (Medical University of Vienna) ;
De Placido, Sabino (Università Degli Studi di Napoli Federico II.) ;
Puglisi, Fabio (Centro di Riferimento Oncologico) ;
Rottey, Sylvie (Uz Gent) ;
Müller, Volkmar (University Medical Center Hamburg-Eppendorf) ;
Ruhstaller, Thomas (Breast Center of Eastern Switzerland) ;
Machiels, Jean-Pascal (Cliniques Universitaires St. Luc) ;
Conte, Pierfranco (University of Padova) ;
Awada, Ahmad (Université Libre de Bruxelles) ;
Jerusalem, Guy (Université de Liège) ;
Universitat Autònoma de Barcelona
Background: COVID-19 appeared in late 2019, causing a pandemic spread. This led to a reorganisation of oncology care in order to reduce the risk of spreading infection between patients and healthcare staff. [...]
2020 -  10.1136/esmoopen-2020-000853
ESMO open, Vol. 5 Núm. 4 (august 2020) , p. e000853
|
|
|
2.
|
|
19 p, 418.6 KB |
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer : Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
/
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Huijberts, Sanne (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Grothey, Axel (West Cancer Center, Germantown, TN) ;
Yaeger, Rona (Memorial Sloan Kettering Cancer Center) ;
Cuyle, Pieter-Jan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Fakih, Marwan (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Peeters, Marc (University Hospital Antwerp (Bèlgica)) ;
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Wasan, Harpreet (Hammersmith Hospital (Londres)) ;
Desai, Jayesh (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) ;
Ciardiello, Fortunato (University of Campania "Luigi Vanvitelli" (Nàpols, Itàlia)) ;
Gollerkeri, Ashwin (Array BioPharma Inc) ;
Christy-Bittel, Janna (Array BioPharma Inc) ;
Maharry, Kati (Array BioPharma Inc) ;
Sandor, Victor (Array BioPharma Inc) ;
Schellens, Jan H. M. (Utrecht University) ;
Kopetz, Scott (The University of Texas MD Anderson Cancer Center, Houston, TX) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Vall d'Hebron Institut de Recerca (VHIR)
To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( identifier: ; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). [...]
2019 - 10.1200/JCO.18.02459
Journal of Clinical Oncology, Vol. 37 (march 2019) , p. 1460-1469
|
|
|
3.
|
|
13 p, 4.9 MB |
Earlier initiation of antiretroviral treatment coincides with an initial control of the HIV-1 sub-subtype F1 outbreak among men-having-sex-with-men in Flanders, Belgium
/
Vinken, L. (KU Leuven. Rega Institute for Medical Research) ;
Fransen, K. (Institute of Tropical Medicine Antwerp (Bèlgica)) ;
Cuypers, L. (KU Leuven. Rega Institute for Medical Research) ;
Alexiev, I. (National Reference Confirmatory Laboratory of HIV. National Center of Infectious and Parasitic Diseases) ;
Balotta, C. (Infectious Diseases and Immunopathology Section. 'L. Sacco' Department of Biomedical and Clinical Sciences. 'L. Sacco' Hospital. University of Milan) ;
Debaisieux, L. (AIDS Reference Laboratory. CUB-Hopital Erasme. Université Libre de Bruxelles) ;
Seguin-Devaux, C. (Laboratory of Retrovirology. Department of Infection and Immunity. Luxembourg Institute of Health) ;
Ribas, S. G. (Institute of Tropical Medicine Antwerp (Bèlgica)) ;
Gomes, P. (Centro de Investigação Interdisciplinar Egas Moniz. Instituto Universitário Egas Moniz) ;
Incardona, F. (EuResist Network GEIE) ;
Kaiser, Rolf (Institute of Virology. University of Cologne) ;
Ruelle, J. (Unit of Medical Microbiology. Institute of Experimental and Clinical Research. Université Catholique de Louvain) ;
Sayan, M. (Research Center of Experimental Health Sciences. Near East University) ;
Paraschiv, S. (Molecular Diagnostics Laboratory. National Institute for Infectious Diseases 'Matei Bals') ;
Paredes, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Peeters, Marc (UMI 233 TransVIHMI/INSERM1175. Institut de Recherche pour le Développement. University of Montpellier) ;
Sönnerborg, A. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Vancutsem, E. (AIDS Reference Laboratory. Department of Microbiology and Infection Control. Universitair Ziekenhuis Brussel) ;
Vandamme, A. M. (Unidade de Microbiologia. Center for Global Health and Tropical Medicine. Instituto de Higiene e Medicina Tropical. Universidade Nova de Lisboa) ;
Van den Wijngaert, S. (AIDS Reference Laboratory. Department of Microbiology. Saint-Pierre University Hospital) ;
Van Ranst, M. (University Hospitals Leuven (Bèlgica)) ;
Verhofstede, C. (AIDS Reference Laboratory. Department of Clinical Chemistry. Microbiology and Immunology. Ghent University) ;
Stadler, T. (Swiss Institute of Bioinformatics) ;
Lemey, P. (KU Leuven. Rega Institute for Medical Research) ;
Van Laethem, K. (University Hospitals Leuven (Bèlgica)) ;
Universitat Autònoma de Barcelona
Human immunodeficiency virus type 1 (HIV-1) non-B subtype infections occurred in Belgium since the 1980s, mainly amongst migrants and heterosexuals, whereas subtype B predominated in men-having-sex-with-men (MSM). [...]
2019 - 10.3389/fmicb.2019.00613
Frontiers in microbiology, Vol. 10 (march 2019) , p. 613
|
|
|
4.
|
|
7 p, 242.6 KB |
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies
/
Boeckx, N. (University Hospital Antwerp (Bèlgica)) ;
Koukakis, R. (Biostatistics, Amgen Ltd) ;
Op de Beeck, K. (University Hospital Antwerp (Bèlgica)) ;
Rolfo, Christian (University Hospital Antwerp (Bèlgica)) ;
Van Camp, G. (University Hospital Antwerp (Bèlgica)) ;
Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Douillard, Jean-Yves (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ;
André, Thierry (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ;
Peeters, Marc (University Hospital Antwerp (Bèlgica))
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of oncology, Vol. 28 (april 2017) , p. 1862-1868
|
|
|
5.
|
|
7 p, 770.6 KB |
Proxies of quality of life in metastatic colorectal cancer : analyses in the RECOURSE trial
/
Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ;
Falcone, Alfredo (Azienda Ospedaliero-Universitaria Pisana) ;
García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ;
Komatsu, Yoshito (Hokkaido University Hospital) ;
Pastorino, Alessandro (IRCCS AOU San Martino IST) ;
Peeters, Marc (University Hospital Antwerp (Bèlgica)) ;
Shimada, Yasuhiro (National Cancer Center Hospital) ;
Yamazaki, Kentaro (Shizuoka Cancer Center) ;
Yoshino, Takayuki (National Cancer Center Hospital East) ;
Zaniboni, Alberto (Fondazione Poliambulanza) ;
Amellal, Nadia (Institut de Recherches Servier) ;
Kanehisa, Akira (Institut de Recherches Servier) ;
Winkler, Robert (Taiho Oncology) ;
Makris, Lukas (Taiho Oncology) ;
Mayer, Robert J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Ohtsu, Atsushi (National Cancer Center Hospital East) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina)
In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). [...]
2017 - 10.1136/esmoopen-2017-000261
ESMO open, Vol. 2 (november 2017)
|
|
|
6.
|
|
1 p, 41.2 KB |
A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium
/
Vinken, L. ;
Fransen, K. ;
Pineda-Peña, A. C. ;
Alexiev, I. ;
Balotta, C. ;
Debaisieux, L. ;
Devaux, C. ;
García Ribas, S. ;
Gomes, P. ;
Incardona, F. ;
Kaiser, Rolf ;
Ruelle, J. ;
Sayan, M. ;
Paraschiv, S. ;
Paredes, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Peeters, Marc ;
Sonnerborg, A. ;
Vancutsem, E. ;
Van den Wijngaert, S. ;
Van Ranst, M. ;
Verhofstede, C. ;
Vandamme, A.-M. ;
Lemey, P. ;
Van Laethem, K. ;
Universitat Autònoma de Barcelona
2017 - 10.5935/1518-0557.20170039
Virus Evolution, Vol. 3 (march 2017)
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
